Surge

Surge provides a biomarker discovery platform that utilizes a proprietary biological fingerprinting technology called Stabl to translate multiomic data into clinical insights. The company's first product line, PreCyte, focuses on predicting postoperative complications to help clinicians personalize perioperative care. Their services target hospitals and the broader precision medicine market, including diagnostics and therapeutic development.